2018 Biopharma CEO Compensation Packages by John Carroll — on May 5, 2019 08:40 AM EDT | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

2018 Biopharma CEO Compensation Packages by John Carroll — on May 5, 2019 08:40 AM EDT

Reporter: Aviva Lev-Ari, PhD, RN

What we know so far:

Chart

CEO	Company	2018	2017	% change
Stéphane Bancel	Moderna	$58.0 million
Kåre Schultz	Teva	$32.5 million	$17 million (2 months)	+91%
John Oyler	BeiGene	$27.9 million	$10.3 million	+170%
Len Schleifer	Regeneron	$26.5 million	$26.5 million	0%
John Milligan	Gilead	$26.0 million	$15.4 million	+69%
Nick Leschly	bluebird bio	$24 million	$8.7 million	+176%
Richard Gonzalez	AbbVie	$21.3 million	$22.6 million	-5%
Ken Frazier	Merck	$20.9 million	$17.6 million	+19%
Alex Gorsky	J&J	$20 million	$29.8 million	-33%
Ian Read	Pfizer	$19.5 million	$27.5 million	-29%
Giovanni Caforio	Bristol-Myers Squibb	$19.4 million	$18.7 million	+4%
Jeff Leiden	Vertex	$18.8 million	$17.2 million	+9%
Robert Bradway	Amgen	$18.5 million	$16.8 million	+10%
Clay Siegall	Seattle Genetics	$18.1 million	$8.6 million	+110%
David Ricks	Eli Lilly	$17.2 million	$15.8 million	+9%
Ludwig Hantson	Alexion	$16.5 million	$15.3 million	+8%
Mark Alles	Celgene	$16.2 million	$13.1 million	+23%
Michel Vounatsos	Biogen	$16.2 million	$13.6 million	+18%
Martine Rothblatt	United Therapeutics	$16 million	$37 million	-57%
Pascal Soriot	AstraZeneca	$14.8 million	$13.62 million	+11%
Severin Schwan	Roche	$11.76 million	$11.68 million	+0.7%
Vas Narasimhan	Novartis	$9.9 million	N/A (first year)	N/A
Hervé Hoppenot	Incyte	$9.3 million	$16 million	-42%
Olivier Brandicourt	Sanofi	$8.1 million	$10.8 million	-25%
Emma Walmsley	GlaxoSmithKline	$7.67 million	$6.4 million	+20%

As of April 30, 2019

SOURCE